Actively Recruiting
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor
Led by Peking Union Medical College Hospital · Updated on 2025-08-05
50
Participants Needed
1
Research Sites
12 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of 68GA-DOTA-dPNE PET/CT imaging to observe how this tracer binds to lesions in patients with malignant tumors. This study aims to assess the expression of CD73 in these tumors and explore the tracer's potential in diagnosing malignant tumors, guiding treatment, and predicting responses to targeted therapy. The study is interventional and involves adults aged 18 to 70 years with malignant tumors. Participants will receive an intravenous injection of the 68GA-DOTA-dPNE tracer during the PET/CT imaging procedure. This imaging helps visualize tumor lesions and measure tracer uptake. The study does not involve any placebo or comparison group but focuses on evaluating the tracer's behavior in malignant tumor patients. The treatment and imaging occur in a controlled clinical setting. During the study, researchers will measure the lesion SUV value immediately after the PET scan to evaluate tracer uptake. Participants must provide written informed consent and be able to follow up as required. The study excludes individuals with severe liver or kidney dysfunction, those who cannot lie flat for 30 minutes, or individuals with claustrophobia or certain mental illnesses. Women who are pregnant, breastfeeding, planning pregnancy, or not using effective contraception are also excluded. The trial will end by March 30, 2026, with participation lasting through the imaging and follow-up period as needed.
CONDITIONS
Brief Title
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older with expected survival of at least 12 weeks
- No prior radiotherapy or chemotherapy and able to undergo surgery or biopsy for pathological diagnosis
- At least one measurable target lesion according to RECIST version 1.1
- Able to provide written informed consent and willing to follow up as required
You will not qualify if you...
- Severe liver or kidney dysfunction
- Women who are pregnant, breastfeeding, planning pregnancy, or not using effective contraception during the study
- Unable to lie flat for 30 minutes
- Claustrophobia or other mental illnesses
- Other medical conditions deemed unsuitable by researchers
- Refusal to join the clinical study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants receive an intravenous administration of the 68GA-DOTA-dPNE tracer followed by PET/CT imaging to diagnose malignant tumors.
1 imaging visit (in-person)
Trial Site Locations
Total: 1 location
1
PUMCH
Dongcheng, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
C
Chenhao Jia
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here